Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Otonomy, Inc. (OTIC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.8400-0.1000 (-5.15%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close1.9400
Open1.9600
Bid1.5900 x 1300
Ask1.8900 x 1200
Day's Range1.8000 - 1.9800
52 Week Range1.1400 - 2.5900
Volume45,102
Avg. Volume159,601
Market Cap104.736M
Beta (5Y Monthly)1.65
PE Ratio (TTM)N/A
EPS (TTM)-0.7800
Earnings DateAug 02, 2022 - Aug 08, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for OTIC

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Otonomy, Inc.
    Technical Assessment: Bearish in the Intermediate-TermFollowing April's miserable performance, May isn't shaping up much better, at least so far. The S&P 500 took a 9% drubbing into April, and 14 trading days into the new month the index is off another (almost) 6%. Since its closing peak on January 3 at 4,796.56, the "500" made a minor new low on Thursday and is down 896 points (or 18.7)%. The Nasdaq has declined 29% from its November 2021 closing high, while the Nasdaq 100 is off 28%.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • GlobeNewswire

    Otonomy to Participate in the H.C. Wainwright Global Investment Conference

    SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its participation in the H.C. Wainwright Global Investment Conference (Hybrid Conference). A pre-recorded company presentation by the Otonomy management team will be available on the conference website beginning at 7 a.m. ET / 4 a.m. PT on May 24, 2022. A link to the presentation will also become available a

  • GlobeNewswire

    Otonomy Announces OTO-825 Presentation at the American Society of Gene & Cell Therapy Annual Meeting

    SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the presentation of preclinical data for OTO-825 at the upcoming American Society of Gene & Cell Therapy (ASGCT) Meeting being held May 16-19 in Washington, DC. Dr. Phillip Uribe from Otonomy will be making a podium presentation entitled “Preclinical Development of an AAV-based Gene Therapy (OTO-825) for Con

  • Motley Fool

    Otonomy (OTIC) Q1 2022 Earnings Call Transcript

    Joining me on the call from Otonomy are Dr. David Weber, president and chief executive officer; and Paul Cayer, chief financial and business officer. Before I turn the call over to Dr. Weber, I would like to remind you that today's call will include forward-looking statements based on current expectations.

Advertisement
Advertisement